Baidu
map

Chest:与AECOPD患者病情有关的有一重要因素!

2018-02-25 MedSci MedSci原创

中等程度肾上腺髓质素原(MR-proADM)水平的升高与COPD患者不同疾病状态的预后不良有关。目前,尚未有研究评估稳定状态MR-proADM与需要住院治疗(严重AECOPD)的COPD急性加重患者或COPD患者社区获得性肺炎(CAP)之间的相关性。近期,一项发表在杂志Chest上的研究旨在评估稳定状态MR-proADM与严重AECOPD和COPD患者伴发CAP的关系。这项研究汇集了来自COMIC

中等程度肾上腺髓质素原(MR-proADM)水平的升高与COPD患者不同疾病状态的预后不良有关。目前,尚未有研究评估稳定状态MR-proADM与需要住院治疗(严重AECOPD)的COPD急性加重患者或COPD患者社区获得性肺炎(CAP)之间的相关性。

近期,一项发表在杂志Chest上的研究旨在评估稳定状态MR-proADM与严重AECOPD和COPD患者伴发CAP的关系。

这项研究汇集了来自COMIC和PROMISE-COPD队列研究的1285名患者的数据。比较先前定义的稳定状态下具有高(> 0.87nmol/l)或低(<0.87nmol/l)血浆MR-proADM水平的患者的第一次严重AECOPD的时间。对于第一次CAP的时间,只有COMIC数据(n = 795)可用。

此项研究结果显示:与低水平MR-proADM的患者相比,具有高水平稳定状态MR-proADM的COPD患者发生AECOPD的风险显著增高,校正风险比(cHR)为1.30(95%CI,1.01-1.68)。单因素分析显示,具有高水平稳定状态MR-proADM的患者发生CAP的风险也显着高于具有低水平MR-proADM的COPD患者(HR 1.93; 95%CI,1.24 - 3.01),但在校正年龄、肺功能和以前AECOPD后,这种相关性不再显着(cHR 1.10; 95%CI,0.68 - 1.80)。

此项研究结果表明:COPD患者的稳定状态高水平MR-proADM与严重的AECOPD相关,但与CAP无关。

原始出处:
Citgez E, Zuur-Telgen M, et al. Stable state MR-proadrenomedullin is associated with severe exacerbations in COPD. Chest. 2018 Feb 20. pii: S0012-3692(18)30264-2. doi: 10.1016/j.chest.2018.02.006.

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765043, encodeId=ee561e65043ac, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 09 06:04:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051066, encodeId=4e5e2051066b6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 30 21:04:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929471, encodeId=073319294e1d4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 27 23:04:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303911, encodeId=9ee1303911a0, content=可以将该指标纳入临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Sun Apr 08 14:03:09 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488824, encodeId=4a0c148882449, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575030, encodeId=fd5115e503060, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765043, encodeId=ee561e65043ac, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 09 06:04:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051066, encodeId=4e5e2051066b6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 30 21:04:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929471, encodeId=073319294e1d4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 27 23:04:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303911, encodeId=9ee1303911a0, content=可以将该指标纳入临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Sun Apr 08 14:03:09 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488824, encodeId=4a0c148882449, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575030, encodeId=fd5115e503060, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765043, encodeId=ee561e65043ac, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 09 06:04:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051066, encodeId=4e5e2051066b6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 30 21:04:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929471, encodeId=073319294e1d4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 27 23:04:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303911, encodeId=9ee1303911a0, content=可以将该指标纳入临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Sun Apr 08 14:03:09 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488824, encodeId=4a0c148882449, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575030, encodeId=fd5115e503060, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-05-27 Smile2680
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765043, encodeId=ee561e65043ac, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 09 06:04:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051066, encodeId=4e5e2051066b6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 30 21:04:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929471, encodeId=073319294e1d4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 27 23:04:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303911, encodeId=9ee1303911a0, content=可以将该指标纳入临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Sun Apr 08 14:03:09 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488824, encodeId=4a0c148882449, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575030, encodeId=fd5115e503060, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-04-08 871538379

    可以将该指标纳入临床

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1765043, encodeId=ee561e65043ac, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 09 06:04:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051066, encodeId=4e5e2051066b6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 30 21:04:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929471, encodeId=073319294e1d4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 27 23:04:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303911, encodeId=9ee1303911a0, content=可以将该指标纳入临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Sun Apr 08 14:03:09 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488824, encodeId=4a0c148882449, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575030, encodeId=fd5115e503060, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-27 gous
  6. [GetPortalCommentsPageByObjectIdResponse(id=1765043, encodeId=ee561e65043ac, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 09 06:04:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051066, encodeId=4e5e2051066b6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 30 21:04:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929471, encodeId=073319294e1d4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 27 23:04:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303911, encodeId=9ee1303911a0, content=可以将该指标纳入临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Sun Apr 08 14:03:09 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488824, encodeId=4a0c148882449, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575030, encodeId=fd5115e503060, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Feb 27 02:04:00 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-27 fengyi817

相关资讯

Thorax:COPD急性加重期气道病原体的季节动态性分析!

由此可见,AECOPD病因随季节的变化而变化。在冬季发病率上升可能是因为增加的病原体以及NTHi呼吸道感染和病毒感染效应之间的相互作用。

慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(草案)

慢性阻塞性肺疾病(chronic obstructive pulmonary  disease,COPD)简称慢阻肺,是一种严重危害人类健康的常见病、多发病。我国对7个地区20  245名成年人进行调查,40岁以上人群中慢阻肺患病率高达8.2%。世界银行,世界卫生组织的资料表明,到2020年慢阻肺将位居世界疾病经济负担的第5位,全球死亡原因的第3位。慢阻肺患者每年约发生0.5~

Thorax:AECOPD患者使用呼气正压治疗不能显著改善预后

呼气正压(PEP)是一种在慢性阻塞性肺疾病急性发作(AECOPD)期用于增强痰液清除的技术。PEP治疗对急性发作期的临床重要预后的影响尚不明确。为了了解PEP治疗对AECOPD患者的症状、生活质量和未来病情加重的影响,来自澳大利亚拉筹伯大学理疗学院的Osadnik CR教授等研究人员进行了一项多中心研究。研究结果在线发表于2013年11月27日的《胸部》(Thorax)杂志上。研究表明AECOPD

Diabetes Obes Metab:AECOPD泼尼松诱导的高血糖采用达格列净的疗效分析!

由此可见,相比于安慰剂,AECOPD治疗期间泼尼松诱导高血糖患者采用达格列净治疗并没有得到更好的血糖控制。

Crit Care:神经调节辅助通气对慢性阻塞性肺疾病急性加重期患者的气流分布和死腔的影响!

由此可见,在AECOPD患者增加ROI4通气分布和减少死腔上NAVA优于PSV。

Baidu
map
Baidu
map
Baidu
map